Yarrow Bioscience, Inc.: Spruce Street Capital LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Spruce Street Capital LP disclosed a stake of more than 5% in Yarrow Bioscience, Inc. via a Schedule 13G filing with the SEC (accession 0000902664-26-004528). The 13G designation indicates a passive investment position rather than an activist one, though the filing did not specify the exact share count or percentage held. Crossing the 5% threshold makes Spruce Street a beneficial owner subject to ongoing SEC disclosure requirements. The disclosure signals notable institutional interest in the bioscience company. Investors will watch for further filings or amendments that clarify the precise size of the position and whether Spruce Street adjusts its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Yarrow Bioscience, Inc., Spruce Street Capital LP